Financials

  • Market Capitalization 10.4 B
  • Employee 295
  • Founded 2016
  • CEO N/A
  • Website www.krystalbio.com
  • Headquarter Pennsylvania, United States
  • FIGI BBG00HDGRHH7
  • Industry Biotechnology
Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
36.04
Price to sales ratio
18.98

Related tickers

#NamePrice24h %7d %1M %1Y %Market CapLast 7 Days
870
SMMT
Summit Therapeutics Inc. - Common Stock
13.73 USD-4.19%+5.05%+7.35%-30.87%10.95 B USD
889
AXSM
Axsome Therapeutics, Inc. - Common Stock
199.02 USD-3.51%-3.86%-13.19%+52.86%10.42 B USD
910
IONS
Ionis Pharmaceuticals, Inc. - Common Stock
61.05 USD-2.21%+0.74%+13.22%-15.36%10.15 B USD
918
CYTK
Cytokinetics, Incorporated - Common Stock
72.09 USD-7.46%-6.75%-8.04%+24.08%10.02 B USD

Frequently asked questions about Krystal Biotech, Inc. Common Stock

What is the Krystal Biotech, Inc. Common Stock stock price today?

The current price of Krystal Biotech, Inc. Common Stock (KRYS) is 351.46. Over the past 24 hours, the stock has changed by -1.68%. Follow the KRYS chart for real-time price dynamics.

What is the stock ticker of Krystal Biotech, Inc. Common Stock?

Krystal Biotech, Inc. Common Stock trades under the ticker KRYS. Tickers can differ by exchange, so always check the exchange and instrument details before trading.

Is Krystal Biotech, Inc. Common Stock stock going up?

KRYS has changed by +2.31% over the last week, -3.98% over the last month, and +87.82% over the last year. Review the chart to see whether the current move is part of a broader trend.

What is the market capitalization of Krystal Biotech, Inc. Common Stock?

Krystal Biotech, Inc. Common Stock currently has a market capitalization of 10.4 B. Market capitalization reflects the total market value of a company's outstanding shares and is commonly used to compare companies by size.

What were Krystal Biotech, Inc. Common Stock earnings last quarter?

Last quarter, Krystal Biotech, Inc. Common Stock reported earnings of 1.85 per share. Earnings per share is one of the key metrics investors use to evaluate a company's profitability and financial performance.

What was Krystal Biotech, Inc. Common Stock revenue for the last quarter?

Krystal Biotech, Inc. Common Stock reported quarterly revenue of 119.22 M. Revenue is one of the main indicators used to evaluate the company's business growth and operating scale.

What was Krystal Biotech, Inc. Common Stock net income for the last quarter?

Krystal Biotech, Inc. Common Stock reported net income of 54.77 M for the last quarter. The previous quarter showed 55.93 M, which means net income changed by -2.08%.

How many employees does Krystal Biotech, Inc. Common Stock have?

As of the latest available data, Krystal Biotech, Inc. Common Stock has 295 employees. Workforce size can provide additional context about the company's scale and operations.

What is Krystal Biotech, Inc. Common Stock EBITDA?

Krystal Biotech, Inc. Common Stock EBITDA is 59.82 M, and its EBITDA margin is 50.17%. EBITDA is commonly used to evaluate operating performance before interest, taxes, depreciation, and amortization.

How can I buy Krystal Biotech, Inc. Common Stock stock?

You can buy Krystal Biotech, Inc. Common Stock (KRYS) through a broker that provides access to the relevant stock exchange. Before trading, check commissions, execution conditions, account type, and whether the stock fits your investment plan.

Should I invest in Krystal Biotech, Inc. Common Stock stock?

Investing in Krystal Biotech, Inc. Common Stock requires reviewing its financial statements, valuation, earnings outlook, news, technical picture, and market risks. Use the KRYS chart and related analysis on metatrader.com as part of your research.

News